Journal article

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.

Abstract:: Background

Findings from previous studies showed that mepolizumab significantly reduces the rate of exacerbations in patients with severe eosinophilic asthma. To assess the relationship between baseline blood eosinophil counts and efficacy of mepolizumab we did a secondary analysis of data from two studies, stratifying patients by different baseline blood eosinophil thresholds.

Methods

We did a post-hoc analysis of data, which was completed on Sept 25, 2015, from t...
Expand abstract
Collapse abstract

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Ortega, H., Yancey, S., Mayer, B., Gunsoy, N., Keene, O., Bleecker, E., Brightling, C., & Pavord, I. (2016). Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respiratory Medicine.

MLA Style

Ortega, H, et al. “Severe Eosinophilic Asthma Treated with Mepolizumab Stratified by Baseline Eosinophil Thresholds: a Secondary Analysis of the DREAM and MENSA Studies.” Lancet Respiratory Medicine, 2016.

Chicago Style

Ortega, H, S Yancey, B Mayer, et al. 2016. “Severe Eosinophilic Asthma Treated with Mepolizumab Stratified by Baseline Eosinophil Thresholds: a Secondary Analysis of the DREAM and MENSA Studies.” Lancet Respiratory Medicine.
Print

Access Document

Publisher copy:: 10.1016/S2213-2600(16)30031-5

Authors

+ Ortega, H More by this author

Role:: Author

+ Yancey, S More by this author

Role:: Author

+ Mayer, B More by this author

Role:: Author

+ Gunsoy, N More by this author

Role:: Author

+ Keene, O More by this author

Role:: Author

More authors...

+ GlaxoSmithKline More from this funder

Publisher:: Elsevier
Journal:: Lancet Respiratory Medicine More from this journal
Publication date:: 2016-05-01
DOI:: 10.1016/S2213-2600(16)30031-5
EISSN:: 2213-2619
ISSN:: 2213-2600

Language:: English
Pubs id:: pubs:623376
UUID:: uuid:9767397e-97be-4d77-ad84-988750ea0271
Local pid:: pubs:623376
Source identifiers:: 623376
Deposit date:: 2016-05-31
ARK identifier:: ark:/29072/ora_9767397e97be4d77ad84988750ea0271

Terms of use

Copyright date:: 2016

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP